---
title: "Gilead Q2 FY26 loss per share widens to $(8.45); revenue rises 10% to $7.8 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294863949.md"
description: "Gilead Sciences reported Q2 FY26 revenue of $7.8 billion, up 10%, but diluted EPS widened to a loss of $8.45 due to $11.2 billion in acquired in-process R&D charges from Arcellx and others. HIV sales rose 12% to $5.7 billion, driven by Biktarvy and Descovy. Trodelvy sales grew 26%. The company raised full-year product sales guidance to $30.1–$30.4 billion."
datetime: "2026-08-04T20:09:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294863949.md)
  - [en](https://longbridge.com/en/news/294863949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294863949.md)
generator: "portal-rs"
---

# Gilead Q2 FY26 loss per share widens to $(8.45); revenue rises 10% to $7.8 billion

-   Gilead posted Q2 2026 revenue up 10% to USD 7.8 billion, while diluted EPS swung to a loss of USD 8.45. \* Acquired in-process R&D charges totaled USD 11.2 billion, tied mainly to the Arcellx, Tubulis and Ouro Medicines acquisitions. \* HIV sales rose 12% to USD 5.7 billion, with Biktarvy up 7% to USD 3.8 billion; Descovy jumped 48% to USD 967 million. \* Trodelvy sales climbed 26% to USD 457 million, while Veklury revenue fell 81% to USD 23 million; cell therapy slid 14% to USD 417 million. \* FY 2026 product sales guidance edged up to USD 30.1 billion–USD 30.4 billion, while diluted loss per share outlook widened to USD 3.75–USD 3.4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804436824) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [ACLX.US](https://longbridge.com/en/quote/ACLX.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run](https://longbridge.com/en/news/297410206.md)
- [FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients](https://longbridge.com/en/news/297236507.md)
- [Parallax Volatility Advisers L.P. Trims Holdings in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/297162579.md)
- [Gilead breaks ground on Foster City biologics facility in $32 billion US investment push](https://longbridge.com/en/news/297254548.md)
- [European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status | GILD Stock News](https://longbridge.com/en/news/296773236.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**